Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 0.62 |
| ▸ | MTOR | P42345 | 17/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241494 | 1.00 | ATM (0.62) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17241458 | 0.96 | ATM (0.61) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17241474 | 0.93 | ATM (0.61) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17241472 | 0.92 | ATM (0.60) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17241449 | 0.92 | ATM (0.62) | ATMMTORPIK3CAATR | |
| SCHEMBL17241457 | 0.90 | ATM (0.62) | ATMMTORPIK3CAKCNH2 | |
| SCHEMBL17241726 | 0.89 | ATM (0.61) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18824924 | 0.87 | ATM (0.59) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17241437 | 0.86 | ATM (0.63) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17241453 | 0.86 | ATM (0.63) | ATMMTORPIK3CAKCNH2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140303-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015170081-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | WO | disclosed |